EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Monoaminergic signatures of treatment-response heterogeneity in schizophrenia: a neuromelanin MRI study

Fumihiko Ueno iD, Shiori Honda, Shinichiro Nakajima iD, Clifford M Cassidy, Yusuke Iwata, Guillermo Horga, Edgardo Torres-Carmona iD, Jianmeng Song, Takahide Etani iD, Saki Homma, Shunya Sekihara, Sakiko Tsugawa und 5 weitere

Psychological Medicine · 2026 · 56

DOI: 10.1017/s0033291726106576 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Psychological Medicine, online erschienen am 09.11.2026. Verfasst von Fumihiko Ueno und 16 weiteren Autor:innen. Beteiligte Einrichtung: Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada. Hauptthemen laut MEDLINE: Melanins, Locus Coeruleus, Antipsychotic Agents, Schizophrenia. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Brain and Behavior Research Foundation, Japan Agency for Medical Research and Development, CIHR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neuromelanin-sensitive MRI (NM-MRI) provides a noninvasive measure of signal within monoaminergic nuclei, including the substantia nigra/ventral tegmental area (SN–VTA) and locus coeruleus (LC). These signals are thought to reflect long-term monoaminergic-related processes. Although presynaptic dopamine dysfunction is implicated in schizophrenia, the contribution of monoaminergic-related NM-MRI signal alterations to treatment-response heterogeneity, including clozapine nonresponse, remains unclear.

Methods

We conducted a cross-sectional NM-MRI study, including patients with ultra-resistant schizophrenia (URS; n = 16), clozapine-responsive treatment-resistant schizophrenia (non-URS; n = 16), first-line antipsychotic responders (FLR; n = 20), and healthy controls (HCs; n = 26). NM-MRI contrast ratios (CR) were quantified in the SN–VTA and LC. Group differences were assessed using covariate-adjusted models, and voxel-wise analyses were performed to localize SN–VTA effects.

Results

SN–VTA CR was higher in both URS ( d = 1.01) and FLR ( d = 0.94) than in HCs, with voxel-wise analyses localizing these effects mainly to dorsal SN–VTA regions. In contrast, LC CR was higher in URS than in FLR ( d = 0.99), whereas URS did not differ significantly from HCs. NM-MRI signals were not associated with symptom severity or cognitive measures.

Conclusions

These findings support the view that schizophrenia treatment-response subgroups may differ in long-term monoaminergic-related (NM-MRI) signal patterns. Elevated NM-MRI signal within dopaminergic nuclei may characterize both antipsychotic-responsive and clozapine nonresponsive schizophrenia, whereas additional noradrenergic involvement may contribute to severe treatment resistance. NM-MRI may help characterize biologically meaningful heterogeneity within treatment-resistant schizophrenia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelaninsLocus CoeruleusAntipsychotic AgentsSchizophreniaSubstantia NigraSchizophrenia, Treatment-ResistantVentral Tegmental AreaHumansMagnetic Resonance ImagingAdultMaleFemaleCross-Sectional StudiesTreatment Effect HeterogeneityClozapineMiddle Aged

Stichwörter der Autor:innen

MRIdopaminelocus coeruleusneuromelaninnoradrenalineschizophreniasubstantia nigratreatment-resistant schizophrenia

Substanzen

MelaninsneuromelaninAntipsychotic AgentsClozapine

Autor:innen und Institutionen

  • Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada.
  • Department of Mental Health, The Ottawa Hospital, Ottawa, Canada.
  • Neuroscience Program, Ottawa Hospital Research Institute, Ottawa, Canada.
  • Department of Psychiatry, University of Ottawa, Ottawa, Canada.
  • Department of Psychiatry and Behavioral Health, Stony Brook University Renaissance School of Medicine, Stony Brook, USA.
  • Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.

ORCID-Profile: Fumihiko Ueno, Shinichiro Nakajima, Edgardo Torres-Carmona, Takahide Etani

Förderung

  • Brain and Behavior Research Foundation
  • Japan Agency for Medical Research and Development
  • CIHR
  • National Alliance for Research on Schizophrenia and Depression
  • Canadian Institutes of Health Research
  • Ontario Mental Health Foundation

Zitieren

APA

Ueno, F., Honda, S., Nakajima, S., Cassidy, C. M., Iwata, Y., Horga, G., Torres-Carmona, E., Song, J., Etani, T., Homma, S., Sekihara, S., Tsugawa, S., de Luca, V., Agarwal, S. M., Remington, G., Gerretsen, P., & Graff-Guerrero, A. (2026). Monoaminergic signatures of treatment-response heterogeneity in schizophrenia: a neuromelanin MRI study. Psychological Medicine, 56. https://doi.org/10.1017/s0033291726106576

Vancouver

Ueno F, Honda S, Nakajima S, Cassidy CM, Iwata Y, Horga G, et al. Monoaminergic signatures of treatment-response heterogeneity in schizophrenia: a neuromelanin MRI study. Psychological Medicine. 2026;56. doi:10.1017/s0033291726106576

BibTeX
@article{Ueno2026,
  author = {Ueno, Fumihiko and Honda, Shiori and Nakajima, Shinichiro and Cassidy, Clifford M and Iwata, Yusuke and Horga, Guillermo and Torres-Carmona, Edgardo and Song, Jianmeng and Etani, Takahide and Homma, Saki and Sekihara, Shunya and Tsugawa, Sakiko and de Luca, Vincenzo and Agarwal, Sri Mahavir and Remington, Gary and Gerretsen, Philip and Graff-Guerrero, Ariel},
  title = {Monoaminergic signatures of treatment-response heterogeneity in schizophrenia: a neuromelanin MRI study},
  journal = {Psychological Medicine},
  year = {2026},
  volume = {56},
  doi = {10.1017/s0033291726106576}
}
Kostenlos starten →